Patents by Inventor Daxing Liu

Daxing Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Engineered liposomes as cancer-targeted therapeutics
    Patent number: 11260132
    Abstract: The disclosure provides liposomes (e.g., cancer-targeting liposomes) with ligands (e.g., EGFR ligands and ICAM-1 ligands) conjugated to liposome surfaces. In some embodiments, the molecular ratio of different ligands complement the relative molecular density (i.e., ratio) of overexpressed protein on the surface of a cell targeted by the liposome (e.g., cancer cell).
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: March 1, 2022
    Assignee: Children's Medical Center Corporation
    Inventors: Marsha A. Moses, Peng Guo, Jiang Yang, Debra Auguste, Daxing Liu
  • PREDICTING TUMOR SPECIFICITY OF TARGETED THERAPEUTICS USING ATOMIC FORCE MICROSCOPY (AFM)
    Publication number: 20200308620
    Abstract: Provided herein are methods of using atomic force microscopy (AFM) to measure the adhesion force between a cell surface target and a ligand (e.g., an antibody) that binds to the cell surface target. Such adhesion force serves as an in vitro metric for predicting the in vivo tumor recognition and/or anti-tumor efficacy of antibody-directed nanomedicine.
    Type: Application
    Filed: October 26, 2018
    Publication date: October 1, 2020
    Applicant: Children's Medical Center Corporation
    Inventors: Marsha A. Moses, Peng Guo, Debra Auguste, Jiang Yang, Daxing Liu
  • ENGINEERED LIPOSOMES AS CANCER-TARGETED THERAPEUTICS
    Publication number: 20200085972
    Abstract: The disclosure provides liposomes (e.g., cancer-targeting liposomes) with ligands (e.g., EGFR ligands and ICAM-1 ligands) conjugated to liposome surfaces. In some embodiments, the molecular ratio of different ligands complement the relative molecular density (i.e., ratio) of overexpressed protein on the surface of a cell targeted by the liposome (e.g., cancer cell).
    Type: Application
    Filed: March 16, 2018
    Publication date: March 19, 2020
    Applicant: Children's Medical Center Corporation
    Inventors: Marsha A. Moses, Peng Guo, Jiang Yang, Debra Auguste, Daxing Liu
  • Cationic polymers as co-drugs for chemotherapeutic agents
    Patent number: 10391112
    Abstract: A method for treating a biological cell is disclosed. The method administers a mixture of a chemotherapeutic drug and a co-drug that facilitates delivery of the chemotherapeutic drug to the nucleus of the cell. Examples of co-drugs include cationic polymers, cationic lipids and cationic proteins. Cationic polymers include a polyethyleneimine (PEI), polylysine, a polybetaaminoester (PBAE), an ?-polylysine (EPL) including ?-poly-L-lysine (e-PLL), a polyarginine peptide, chitosan, a polyamidoamine dendrimer (PAMAM). Cationic lipids include 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP). Cationic proteins include protamine.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: August 27, 2019
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Debra Auguste, Daxing Liu
  • Cationic Polymers As Co-Drugs For Chemotherapeutic Agents
    Publication number: 20180117071
    Abstract: A method for treating a biological cell is disclosed. The method administers a mixture of a chemotherapeutic drug and a co-drug that facilitates delivery of the chemotherapeutic drug to the nucleus of the cell. Examples of co-drugs include cationic polymers, cationic lipids and cationic proteins. Cationic polymers include a polyethyleneimine (PEI), polylysine, a polybetaaminoester (PBAE), an ?-polylysine (EPL) including ?-poly-L-lysine (e-PLL), a polyarginine peptide, chitosan, a polyamidoamine dendrimer (PAMAM). Cationic lipids include 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP). Cationic proteins include protamine.
    Type: Application
    Filed: September 22, 2017
    Publication date: May 3, 2018
    Inventors: Debra Auguste, Daxing Liu
  • Cationic polymers as co-drugs for chemotherapeutic agents
    Patent number: 9795624
    Abstract: A method for treating a biological cell is disclosed. The method administers a mixture of a chemotherapeutic drug and a co-drug that facilitates delivery of the chemotherapeutic drug to the nucleus of the cell. Examples of co-drugs include cationic polymers, cationic lipids and cationic proteins. Cationic polymers include a polyethyleneimine (PEI), polylysine, a polybetaaminoester (PBAE), an ?-polylysine (EPL) including ?-poly-L-lysine (e-PLL), a polyarginine peptide, chitosan, a polyamidoamine dendrimer (PAMAM). Cationic lipids include 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP). Cationic proteins include protamine.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: October 24, 2017
    Assignee: RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK
    Inventors: Debra Auguste, Daxing Liu
  • CATIONIC POLYMERS AS CO-DRUGS FOR CHEMOTHERAPEUTIC AGENTS
    Publication number: 20160324883
    Abstract: A method for treating a biological cell is disclosed. The method administers a mixture of a chemotherapeutic drug and a co-drug that facilitates delivery of the chemotherapeutic drug to the nucleus of the cell. Examples of co-drugs include cationic polymers, cationic lipids and cationic proteins. Cationic polymers include a polyethyleneimine (PEI), polylysine, a polybetaaminoester (PBAE), an ?-polylysine (EPL) including ?-poly-L-lysine (e-PLL), a polyarginine peptide, chitosan, a polyamidoamine dendrimer (PAMAM). Cationic lipids include 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP). Cationic proteins include protamine.
    Type: Application
    Filed: May 4, 2016
    Publication date: November 10, 2016
    Inventors: Debra Auguste, Daxing Liu